<DOC>
	<DOC>NCT01034644</DOC>
	<brief_summary>This study, PRISMS-15 is a single visit, exploratory pharmacogenetic trial and long-term follow-up of the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) trial. The aim of this trial is to provide additional data on the driving factors of IFN beta response and the long-term outcomes of RebifÂ® treatment. This is a Phase IV trial involving subjects who previously participated in the PRISMS trial. To address the trial objectives, a single visit will be performed, at least 3 months after the onset of the last relapse.</brief_summary>
	<brief_title>Pharmacogenetic Trial and Long-term Follow-up of the PRISMS Trial (PRISMS-15)</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Was randomized in the PRISMS study Is willing and able to comply with the protocol Written informed consent given before any trialrelated activities are carried out Is unwilling or unable to participate in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Biomarkers</keyword>
	<keyword>Genetic markers</keyword>
</DOC>